Company intelligence / Profile preview
OrthoTrophix, Inc.
Oakland, California, United Statesorthotrophix.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Phase 2
01
Overview
TPX-100 has demonstrated safety and clinical efficacy in a Phase 2 placebo-controlled study in subjects with knee osteoarthritis across fifteen centers in the U.S. Clinical data shows robust improvements in function, long-term pain reduction, and joint structure, with strong associations between clinical and structural effects[1][2].
- Therapeutic areas
- Rheumatology
- Modalities
- Small molecules (TPX-100)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
American Regent (licensed TPX-100 for the United States)[4]
Beyond the preview
Go deeper on OrthoTrophix, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OrthoTrophix, Inc..